Description

Buy GHRP-6 30mg + Mod GRF 1-29 30mg Blend | EU Research Peptides

Welcome to euresearchpeptides.com — your trusted premium EU-based supplier of high-purity research peptides. We specialize in providing laboratory-grade peptides for serious researchers across Europe, including Germany, France, the Netherlands, Spain, and the United Kingdom. Buy GHRP-6 30mg + Mod GRF 1-29 30mg

Our GHRP-6 30mg + Mod GRF 1-29 30mg blend represents the gold standard for growth hormone research. This synergistic peptide combination is meticulously manufactured for investigators studying the complex mechanisms of the somatotropic axis, pituitary function, and metabolic regulation. Buy GHRP-6 30mg + Mod GRF 1-29 30mg

---

What Is GHRP-6 and Mod GRF 1-29?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It functions as a potent ghrelin receptor (GHS-R1a) agonist, stimulating endogenous growth hormone secretion from the anterior pituitary.

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor 1-29), also known as CJC-1295 without DAC (Drug Affinity Complex), is a tetrasubstituted analog of native GHRH. Its four amino acid substitutions provide enhanced resistance to enzymatic degradation while maintaining full biological activity.

Why This Combination?

Research literature consistently demonstrates that GHRP-6 and Mod GRF 1-29 exhibit significant synergistic effects on GH secretion. When administered together at maximal concentrations, these peptides produce GH release exceeding the sum of their individual effects . This synergy occurs through complementary mechanisms:

• Mod GRF 1-29 activates the adenylyl cyclase/cAMP pathway via GHRH receptors

• GHRP-6 activates the phospholipase C/IP3 pathway via ghrelin receptors

• Combined treatment potentiates intracellular calcium mobilization

---

Technical Specifications

---

Research Applications

Pituitary Function Studies

GHRP-6 and Mod GRF 1-29 are valuable tools for investigating somatotroph cell biology. Research demonstrates that GHRP-6 stimulates GH release in a time- and dose-dependent manner with half-maximal stimulation at 7 × 10⁻⁹ M . Unlike GHRH analogs, GHRP-6 activity is not blocked by GRF receptor antagonists, confirming distinct receptor-mediated mechanisms.

Metabolic Research

Investigators utilize this peptide blend to study:

• Muscle protein synthesis and nitrogen retention

• Adipose tissue metabolism and lipolysis

• Insulin-like growth factor-1 (IGF-1) regulation

• Bone mineral density and osteoblast activity

Studies indicate combined GHRP-6 and GRF administration may increase IGF-1 levels by over 65%, compared to approximately 27-28% with GRF alone .

Neuroendocrine Research

GHRP-6 has been investigated for its effects on:

• Learning and memory consolidation

• Neuroprotection following ischemic events

• Mood regulation and stress response

• Sleep architecture and quality

Research suggests ghrelin mimetics like GHRP-6 may improve spatial cognition and reduce infarct size in stroke models .

Wound Healing and Tissue Repair

Investigations suggest GHRP-6 may stimulate angiogenesis through interaction with CD36 scavenger receptors, promoting new blood vessel formation and collagen synthesis .

---

Quality Assurance

All peptides at euresearchpeptides.com are manufactured in ISO9001 and cGMP-certified facilities. Each batch undergoes rigorous quality control including:

• HPLC-MS purity verification (>99%)

• Mass spectrometry for molecular weight confirmation

• Sterility testing for research-grade safety

• Stability studies for shelf-life validation

---

Reconstitution and Handling Protocols

Recommended Reconstitution

1. Allow lyophilized powder to reach room temperature (20-25°C)

2. Add sterile bacteriostatic water or sterile saline to the vial

3. For 30mg GHRP-6: Add 3mL diluent for 10mg/mL concentration

4. For 30mg Mod GRF 1-29: Add 3mL diluent for 10mg/mL concentration

5. Swirl gently — do not shake

6. Refrigerate at 2-8°C after reconstitution

Storage Recommendations

Solubility

• GHRP-6: Freely soluble in sterile water, bacteriostatic water, and saline solutions

• Mod GRF 1-29: Freely soluble in sterile water and dilute acetic acid solutions

---

Safety Considerations

For Research Use Only — Not for human consumption, therapeutic use, or veterinary applications.

• Use appropriate personal protective equipment (gloves, lab coat, eye protection)

• Handle in a properly equipped laboratory environment

• Do not inject or ingest

• Keep away from children and unauthorized personnel

• Consult Safety Data Sheet (SDS) before handling

• Dispose of unused material according to local regulations

Frequently Asked Questions (FAQ)

1. What is the difference between Mod GRF 1-29 and CJC-1295?

Mod GRF 1-29 is identical to CJC-1295 without the Drug Affinity Complex (DAC). The key difference is half-life: Mod GRF 1-29 has a short half-life (~30 minutes) that mimics natural pulsatile GH release, while CJC-1295 with DAC has a prolonged half-life of 7-8 days. Research suggests pulsatile release may be more physiological than continuous GH elevation (“GH bleed”) .

2. Why combine GHRP-6 with Mod GRF 1-29?

These peptides work through distinct receptor mechanisms:

• Mod GRF 1-29 activates GHRH receptors → cAMP pathway

• GHRP-6 activates ghrelin receptors (GHS-R1a) → IP3/DAG pathway

When combined, they produce synergistic GH release exceeding the sum of individual effects, with studies reporting enhanced IGF-1 elevation of over 65% .

3. What is the recommended research dosage?

For in vivo research models, typical dosages range from 100-300 mcg per kg of body weight for each peptide. The “saturation dose” for both GHRP-6 and Mod GRF 1-29 is approximately 1 mcg per kg or 100 mcg total . Researchers should determine optimal concentrations for their specific experimental protocols.

4. Can GHRP-6 and Mod GRF 1-29 be mixed in the same syringe?

Yes, these peptides are compatible and can be combined in the same syringe for simultaneous administration. However, mixed solutions should be used within a few hours as peptide stability may decrease over time. For best results, reconstitute separately and combine immediately before use .

5. Does GHRP-6 increase prolactin or cortisol?

Research indicates GHRP-6 may elevate prolactin and cortisol levels in some experimental models. For studies requiring minimal off-target effects, investigators may consider GHRP-2 or Ipamorelin, which show different side effect profiles .

6. What are the solubility characteristics of these peptides?

Both peptides are freely soluble in sterile water, bacteriostatic water, and saline solutions. Mod GRF 1-29 may require slightly acidic conditions (dilute acetic acid) for optimal solubility if using distilled water. Always add diluent to the vial, not powder to diluent .

7. How should reconstituted peptides be stored?

Reconstituted peptides should be refrigerated at 2-8°C and used within 30 days. Avoid repeated freeze-thaw cycles as this degrades peptide integrity. For longer-term storage, maintain lyophilized form at -20°C .

8. What quality testing is performed on these peptides?

Each batch undergoes:

• HPLC purity analysis (>99%)

• Mass spectrometry (MS-UPLC) for sequence confirmation

• Residual solvent analysis

• Sterility testing

• Endotoxin screening

9. Are these peptides shipped internationally?

euresearchpeptides.com ships throughout the European Union, including Germany, France, Netherlands, Spain, Italy, Belgium, Austria, and Switzerland. Some restrictions apply to certain compounds in specific countries. Contact our team for country-specific shipping information.

10. What is the legal status of research peptides in Europe?

Research peptides are legal to purchase and possess for laboratory research purposes in most European countries. They are not approved for human consumption or therapeutic use. Customers are responsible for compliance with local regulations regarding research compound importation and use.